| Dr Christina L Kranc, MD | |
|
10200 N 92nd St Ste 205, Scottsdale, AZ 85258-4536 | |
| (602) 494-1817 | |
| Not Available |
| Full Name | Dr Christina L Kranc |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 12 Years |
| Location | 10200 N 92nd St Ste 205, Scottsdale, Arizona |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447505755 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 036141198 (Illinois) | Secondary |
| 208D00000X | General Practice | 125062032 (Illinois) | Secondary |
| 207N00000X | Dermatology | 53000 (Arizona) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southwest Skin Specialists Llc | 9739079864 | 47 |
News Archive
Isis Pharmaceuticals, Inc., the leader in RNA-targeted therapeutics, and Akcea Therapeutics, its wholly owned subsidiary, announced today that The New England Journal of Medicine (NEJM) has published positive clinical results from a Phase 2 clinical study evaluating volanesorsen (formerly ISIS-APOCIII Rx) in patients with very high to severely high triglycerides.
Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today its results for the fourth quarter and full year ended October 31, 2010. Revenues for the fourth quarter were $177.7 million or 0.9 percent higher than the same period last year. Excluding currency fluctuations, current year fourth quarter revenues would have increased by approximately 5.0 percent versus the same period last year.
New data were presented today at the 18th International AIDS Conference from the VERxVE study that show an investigational, once-daily extended-release (400 mg QD) formulation of nevirapine was non-inferior to twice-daily immediate release Viramune® (nevirapine) tablets (200 mg BID), both in combination with Truvada® (tenofovir and emtricitabine) tablets in treatment-naive HIV-1 infected patients through 48 weeks.
Chemists and biologists from the University of Bath have developed a new technique that could be used to diagnose and develop treatments for age-related conditions like Alzheimer's disease, diabetes and cancer.
Breast cancer survivors taking aromatase inhibitors (AIs) such as anastrozole, letrozole, and exemestane experienced a reduction in joint pain if they exercised while on treatment, according to results presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.
› Verified 6 days ago
| Entity Name | Southwest Skin Specialists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174521926 PECOS PAC ID: 9739079864 Enrollment ID: O20040319001063 |
News Archive
Isis Pharmaceuticals, Inc., the leader in RNA-targeted therapeutics, and Akcea Therapeutics, its wholly owned subsidiary, announced today that The New England Journal of Medicine (NEJM) has published positive clinical results from a Phase 2 clinical study evaluating volanesorsen (formerly ISIS-APOCIII Rx) in patients with very high to severely high triglycerides.
Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today its results for the fourth quarter and full year ended October 31, 2010. Revenues for the fourth quarter were $177.7 million or 0.9 percent higher than the same period last year. Excluding currency fluctuations, current year fourth quarter revenues would have increased by approximately 5.0 percent versus the same period last year.
New data were presented today at the 18th International AIDS Conference from the VERxVE study that show an investigational, once-daily extended-release (400 mg QD) formulation of nevirapine was non-inferior to twice-daily immediate release Viramune® (nevirapine) tablets (200 mg BID), both in combination with Truvada® (tenofovir and emtricitabine) tablets in treatment-naive HIV-1 infected patients through 48 weeks.
Chemists and biologists from the University of Bath have developed a new technique that could be used to diagnose and develop treatments for age-related conditions like Alzheimer's disease, diabetes and cancer.
Breast cancer survivors taking aromatase inhibitors (AIs) such as anastrozole, letrozole, and exemestane experienced a reduction in joint pain if they exercised while on treatment, according to results presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Christina L Kranc, MD 5310 Harvest Hill Rd Ste 290, Dallas, TX 75230-5826 Ph: (602) 494-1817 | Dr Christina L Kranc, MD 10200 N 92nd St Ste 205, Scottsdale, AZ 85258-4536 Ph: (602) 494-1817 |
News Archive
Isis Pharmaceuticals, Inc., the leader in RNA-targeted therapeutics, and Akcea Therapeutics, its wholly owned subsidiary, announced today that The New England Journal of Medicine (NEJM) has published positive clinical results from a Phase 2 clinical study evaluating volanesorsen (formerly ISIS-APOCIII Rx) in patients with very high to severely high triglycerides.
Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today its results for the fourth quarter and full year ended October 31, 2010. Revenues for the fourth quarter were $177.7 million or 0.9 percent higher than the same period last year. Excluding currency fluctuations, current year fourth quarter revenues would have increased by approximately 5.0 percent versus the same period last year.
New data were presented today at the 18th International AIDS Conference from the VERxVE study that show an investigational, once-daily extended-release (400 mg QD) formulation of nevirapine was non-inferior to twice-daily immediate release Viramune® (nevirapine) tablets (200 mg BID), both in combination with Truvada® (tenofovir and emtricitabine) tablets in treatment-naive HIV-1 infected patients through 48 weeks.
Chemists and biologists from the University of Bath have developed a new technique that could be used to diagnose and develop treatments for age-related conditions like Alzheimer's disease, diabetes and cancer.
Breast cancer survivors taking aromatase inhibitors (AIs) such as anastrozole, letrozole, and exemestane experienced a reduction in joint pain if they exercised while on treatment, according to results presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.
› Verified 6 days ago
Dr. Pamela Landsteiner Mundell, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 20201 N Scottsdale Healthcare Dr, Scottsdale, AZ 85255 Phone: 480-398-1550 Fax: 480-398-1551 | |
Dr. Anthony John Petelin, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 14275 N 87th St, Suite #110, Scottsdale, AZ 85260 Phone: 480-905-8485 Fax: 480-905-7274 | |
Dr. Gary Anthony Mccracken, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 14275 N 87th St, Suite 110, Scottsdale, AZ 85260 Phone: 480-905-8485 Fax: 480-905-7274 | |
Paul M Petelin Sr., MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 14275 N 87th St, Ste 110, Scottsdale, AZ 85260 Phone: 480-905-8485 Fax: 480-905-7274 | |
Dr. Mark V Dahl, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 13400 E Shea Blvd, Scottsdale, AZ 85259 Phone: 480-301-8000 | |
Mark R Pittelkow, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 13400 E Shea Blvd, Scottsdale, AZ 85259 Phone: 480-301-8508 | |
Dr. Genevieve L Egnatios, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 11333 N Scottsdale Rd Ste 115, Scottsdale, AZ 85254 Phone: 480-998-1400 |